FENC Wutah pendapatan triwulanan Fennec Pharmaceuticals

Simbol lan logo merek Fennec (FENC)

Fennec Pharmaceuticals (FENC) is actively engaging with pediatric oncology centers to expand patient access to therapy. Current quarterly revenue growth illustrates the pace of this expansion, while 57.20 expresses the metric's value today. The commercial surge of PEDMARK within its unique niche is supported by strict FDA oversight and exclusive patents, which create a formidable barrier to entry for competitors.

Fennec (FENC) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 20.11.2026

Fennec Pharmaceuticals Inc. (FENC) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:Fennec Pharma (FENC)
Barang unggulan fennecpharma.com

Fennec Pharmaceuticals (FENC) is scaling sales of its approved oncology drug through market expansion and licensing agreements. The dynamics of these processes are quantified by calculating the percentage change in quarterly revenue, which eliminates subjective forecasts and captures actual cash flow. The current level of quarterly revenue growth confirms the effectiveness of product commercialization under organic development conditions. The stability of this indicator serves as a guarantee of capital preservation and determines the business's margin of safety.

Pesaing utama

INCY - Wutah pendapatan kuartal marang kuartal|Owah-owahan pendapatan dibandhingake kuartal kepungkur HUTCHMED (HCM)|NUVB: Wutah pendapatan triwulanan|Owah-owahan pendapatan dibandhingake kuartal kepungkur Day One Bio DAWN|Wutah dodolan triwulanan MNPR|Tingkat wutah pendapatan sajrone kuartal Inhibrx Biosciences INBX|Wutah dodolan triwulanan IMAB (I-Mab Biopharma Co., Ltd.)|HRTX (Heron Therapeutics Inc) - Tambahing pendapatan triwulanan|Nuvectis Pharma, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal CHRS (Coherus BioSciences)|Corbus Pharma - Wutah pendapatan triwulanan|Tambahing pendapatan triwulanan CRDF (cardiffoncology.com)|BYSI: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal BioAtla Corp (BCAB)|Wutah pendapatan kuartal marang kuartal Lixte Biotechnology Holdings, Inc.|CTXR: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan CLRB|Wutah pendapatan triwulanan BioLineRx Corporation (BLRX)|Wutah pendapatan kuartal marang kuartal Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Dinamika pendapatan kuartal marang kuartal|KZIA: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Silexion Therapeutics|NuCana plc (NCNA) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan Chimerix, Inc|Wutah dodolan triwulanan CYCC|Wutah dodolan triwulanan G1 Therapeutics (GTHX)|Wutah pendapatan kuartal marang kuartal Kronos Bio Corporation (KRON)|Kintara - Wutah dodolan kuartal marang kuartal|Oncternal Therapeutics, Inc. - Wutah dodolan triwulanan|Owah-owahan dodolan kuartal marang kuartal PRTG (Portage)